Hormone therapy: a tale of two cancers – the potential of estrogen/selective estrogen receptor modulator combinations

References

• Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil. Steril.76(1), 25–31 (2001).
   PubMed Web of Science ®Google Scholar
• Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am. J. Obstet. Gynecol.170, 1213–1223 (1994).
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA275, 370–375 (1996).
   PubMed Web of Science ®Google Scholar
• Anderson GL, Judd HL, Kaunitz AM et al.; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA290, 1739–1748 (2003).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD et al.; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA289, 3243–3253 (2003).
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML et al. Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am. J. Epidemiol.167, 1407–1415 (2008).
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA295, 1647–1657 (2006).
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet. Gynecol.113, 65–73 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al.; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295, 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA281, 2189–2197 (1999).
   PubMed Web of Science ®Google Scholar
• Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod. Sci.15, 984–992 (2008).
   PubMed Web of Science ®Google Scholar
• Stovall DW, Utian WH, Gass ML et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause14, 510–517 (2007).
   PubMed Web of Science ®Google Scholar
• Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol. Cell. Endocrinol.287, 40–46 (2008).
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology146, 3999–4008 (2005).
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause16, 1116–1124 (2009).
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause17, 281–289 (2010).
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil. Steril.92, 1045–1052 (2009).
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil. Steril.92, 1039–1044 (2009).
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil. Steril.92, 1025–1038 (2009).
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil. Steril.92, 1018–1024 (2009).
   PubMed Web of Science ®Google Scholar